August 3, 2017 6:28pm
However, I see no end to these choppy trading ranges
This market has not been good to the cell therapy sector but, low and bottom pricing could have its reward … for some equities once we get beyond Q2 financial results!
There is an upside to this bottom which involves positive clinical (data) results, guidance and transparency!
Pre-open indications: 4 hit and 2 miss
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
I answer one question, in which company should investors commit and keep their money.
Thursday’s results have implications to Friday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s investor’s newsletter, “… just what is quantifiable progress these days? This current level of performance is not short, near or even long-term sustainable. At the moment, I don’t see the capacity to evolve or even change… Two words to evoke: guidance and transparency.”
- Volume is still very LOW and higher in selling – again; it is a gauge of negative sentiment and investor non-interest.
Reiterating, “how many ways can I say it, the cell therapy sector is entering the usual weak seasonal period side-by-side with investor pessimistic views of quarterly financial results. Historically, the period from August through October has seen stocks struggle and a period when corrections have tended to occur more than often.”
- Never forget, we are in the middle of Q2 financial result announcements and the pre-release period suffers many a company’s share pricing …
The problem, many CEOs know where their own interests are – forgetting their responsibility to the true owners – investors or in this market ETFs, hedge funds, some mutual funds – it’s time for management teams to better message and communicate – the silence is defining!
Shareholder LOYALTY is MORE than a PRECIOUS commodity!
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The first hour was negative with an A/DL of 13/26 and 4 flats;
· The mid-day was negative with an A/DL of 18/21 and 4 flats;
· The close was positive with an A/DL of 20/18 and 5 flats;
Pre-open indications: 4 hit and 2 miss
- AxoGen (AXGN) closed down -$0.25 – miss;
- bluebird bio (BLUE) closed up +$2.55 – miss;
- Cellectis SA (CLLS) closed up +$0.07 – hit;
- Juno Therapeutics (JUNO) closed up +$0.09 – hit;
- Organovo (ONVO) closed up +$0.01 – hit;
- Spark Therapeutics (ONCE) closed down -$2.87 – hit;
Daily analytics:
U.S. stocks closed mostly lower on Thursday though the Dow bucked the trend to close slightly higher and put in its seventh straight record close. The Dow rose less than 0.1% to 22,026. The S&P 500 fell 5.5 points, or 0.2%, to 2,472.09. The NASDAQ slid 22.3 points to 6,340.3, a decline of 0.4%.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Thursday traded at 10.44, up +1.56% …
- Wednesday traded at 10.24, up +1.49% following Tuesday’s 10.09 down -1.66%, Monday traded 10.30 up +0.10% … Friday closed at 10.29 up +1.78 following last Thursday’s +5.31% to 10.11
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Thursday was down -0.51%
· Wednesday was down -1.07%
· Tuesday was up +0.20%
· Monday down -0.31%
· Friday down -0.28%
· Last Thursday was down -0.64%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Thursday was down -0.79%
· Wednesday was up +0.40% which didn’t help the cell therapy sector
· Tuesday down -1.04%
· Monday down -0.85%
· Friday up +0.63%
· Last Thursday was down -1.87%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %’s migrate…
· Thursday’s decliners ranged from -0.53% <HSGX> to -6.85% <CUR> in 18 equities;
· Wednesday’s decliners ranged from -0.15% <OSIR> to -9.63% <CYTX> in 28 equities;
· Tuesday’s decliners ranged from -0.14% <MESO> to -8.51% <CYTX> in 31 equities;
· Monday’s decliners ranged from -0.03% <IMUC> to -8.16% <FCSC> in 31 equities;
· Friday’s decliners ranged from -0.02% <CYTX> to -12,31% <CAPR> in 25 equities;
· Last Thursday’s decliners ranged from -0.45% <OPXA> to -29.15% <CUR> in 31 equities;
Versus
………… look at the percentage’s (%) and their decreases …….
· Thursday’s gainers ranged from +0.30% <CLLS> to +10.91% <CAPR> in 20 equities;
· Wednesday’s gainers ranged from +0.64% <QURE> to +19.72% <ONCE> in 14 equities;
· Tuesday’s gainers ranged from +0.87% <BLFS> to +5.08% <FCSC> in 8 equities;
· Monday’s gainers ranged from +0.49% <VTGN> to +4.64% <AXGN> in 9 equities;
· Friday’s gainers ranged from +0.27% <XON> to +11.92% <KOOL> in 16 equities;
· Last Thursday’s gainers ranged from +0.28% <FCSC> to +28.71% <CAPR> in 10 equities;
Some of MY working trend lines or indications:
… The greatest volume to the downside: IMUC, ONCE, AXGN, CUR and ADRO
… Upside volume was weighted to: CAPR, NWBO, ONVO, JUNO and BLUE
… Biggest $ downside: ONCE, ADRO, RGNX, AXGN and AGTC
… Largest $ upside: BLUE, KITE, MDXG, BTX and QURE
… Flat: VCEL, ATHX, ISCO, VTGN and SGMO
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
